Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Third-Party Inspection Program 'Here To Stay,' Agency Official Says

This article was originally published in The Gray Sheet

Executive Summary

Despite slow growth, FDA's third-party Accredited Persons (AP) inspection program is "here to stay," an FDA official said. And a new agency initiative with Health Canada has sparked more interest in the use of third parties to perform FDA inspections

You may also be interested in...



FDA, Global Partners Prepare To Ramp Up Single-Audit Program

FDA is strongly encouraging manufacturers to participate in the Medical Device Single Audit Program, set to launch in a pilot phase by June. An agency official points to strong global incentives, particularly for firms pursuing the Brazil and Canada markets.

Good Deal? Firms Seek Details On FDA ISO Audit Report Submission Program

Device makers generally support FDA's plan for accepting voluntary international audit reports as a means for possibly delaying an FDA inspection, but firms say more details need to be spelled out before many will agree to participate

Good Deal? Firms Seek Details On FDA ISO Audit Report Submission Program

Device makers generally support FDA's plan for accepting voluntary international audit reports as a means for possibly delaying an FDA inspection, but firms say more details need to be spelled out before many will agree to participate

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel